Search Results - geoffrey+hill

4 Results

Sort By:

Defining pathogenic IL-17 and CSF-1 gene expression signatures in chronic graftversus-host disease

bdsPredictive Immune Signatures for Chronic Graft Versus Host Disease (cGVHD) Dysregulated immune signatures may be well-suited for their ability to predict the effectiveness of agents targeting IL-17 and CSF-1. Chronic Graft Versus Host Disease (cGVHD) is the leading cause of non-relapse late morbidity and mortality following allogeneic hematopoietic...

Published: 5/2/2025 | Updated: 2/4/2025 | Inventor(s): Geoffrey Hill, Julie Boiko

Keywords(s): Biomarker, Macromolecule, Nucleic Acid

Category(s): Diagnostic

Immunosuppressive Regulatory T cells to Attenuate Autoimmune Disorders, Inflammatory Disorders, and Graft-versus-Host-Diseases

Immunosuppressive Regulatory T cells to Attenuate Autoimmune Disorders, Inflammatory Disorders, and Graft-versus-Host-Diseases Methods to identify, produce, and elicit immune tolerance using TR1 cells Identification of the bona fide transcriptional and cellular control of Type-1 regulatory T (TR1) allows for the therapeutic utilization...

Published: 12/7/2023 | Updated: 5/25/2022 | Inventor(s): Geoffrey Hill, Ping Zhang

Keywords(s): Immuno Oncology

Category(s): Therapeutic

Methods to avoid Graft-versus-Host Disease after allogenic transplant

Methods to avoid Graft-versus-Host Disease after allogenic transplant Methods to prevent or reduce GI tract inflammation by modulating the gut microbiome and immune system Allogeneic hematopoietic stem cell transplantation (HSCT) intends to cure high-risk hematological malignancies, immunodeficiencies, metabolic disease, or a life-threatening...

Published: 2/4/2025 | Updated: 5/25/2022 | Inventor(s): Geoffrey Hill, Motoko Koyama

Keywords(s): Immuno Oncology

Category(s): Therapeutic

Pre-clinical and Clinical Development of Serotherapy for CMV reactivation after transplantation

Pre-clinical and Clinical Development of Serotherapy for Cytomegalovirus (CMV) Reactivation after Transplantation Methods and tools to treat CMV reactivation in immunosuppressed patients using serotherapy Cytomegalovirus (CMV) is a common virus that infects 50-80% of the population by age 40. Although symptoms are generally mild in patients...

Published: 12/27/2023 | Updated: 6/2/2020 | Inventor(s): Geoffrey Hill, Mariapia Degli-Esposti, Peter Fleming, Christopher Andoniou

Keywords(s): Immuno Oncology

Category(s): Therapeutic